Susquehanna International Group
MDNA

Susquehanna International Group’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Susquehanna International Group’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,605
Closed -$3.03K – 13709
2023
Q3 		$3.03K Sell
10,605
-43,127
-80% -$16.8K ﹤0.01% 11823
2023
Q2 		$25.7K Buy
+53,732
New +$33.2K ﹤0.01% 11570
2023
Q1 		– Sell
-48,491
Closed -$22.8K – 13872
2022
Q4 		$22.8K Buy
+48,491
New +$29.6K ﹤0.01% 11718
2022
Q2 		– Sell
-20,861
Closed -$26K – 14314
2022
Q1 		$26K Buy
+20,861
New +$32.4K ﹤0.01% 12555
2021
Q2 		– Sell
-27,823
Closed -$114K – 13470
2021
Q1 		$114K Buy
+27,823
New +$113K ﹤0.01% 11792

Other funds holding MDNA

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
NDSI
Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Susquehanna International Group's MDNA Position: Q4 2023 in Review

Susquehanna International Group sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2023, closing a stake of 10,605 shares — an estimated $3.03K sold.

Susquehanna International Group first reported a position in MDNA in Q1 2021 and held it in 5 quarters. The position peaked at $114K in Q1 2021. 3 funds tracked by Wall St. Rank hold MDNA as of Q4 2023.

  • Susquehanna International Group reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2023 after selling out during the quarter.
  • Susquehanna International Group sold 10,605 Medicenna Therapeutics Corp. Common Shares shares in Q4 2023, an estimated $3.03K.
  • Susquehanna International Group first reported a position in Medicenna Therapeutics Corp. Common Shares in Q1 2021 and held it in 5 quarters.
  • Susquehanna International Group's Medicenna Therapeutics Corp. Common Shares position peaked at $114K in Q1 2021.
  • 3 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2023.

Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.